Tenaya Therapeutics

TENAYA THERAPEUTICS INC

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.

FSUN

MTDR

TNYA


Insider buying picked up for Matador Resources (NYSE:MTDR), Tenaya Therapeutics (NASDAQ:TNYA), and FirstSun Capital Bancorp (NASDAQ:FSUN) in March. These companies rank high, if not in first position, for the number of

Top 3 Insider Stock Buys in March—Are They Still Good in April?

Closeup,Of,Wall,St.,Street,Sign,And,Large,New,York

Earnings

Equities

Government

Market Summary

News

Futures

Commodities

Economics

Pre-Market Outlook

Markets

Analyst Ratings

BDSX

CRWD

GDOT

SPGC

SPHR

U.S. stock futures declined on Tuesday following the worst trading day of 2025 on Monday. Futures fell in premarket trading except Nasdaq 100.

US Futures Tumble As Traders Await Trump&#39;s Congress Address: &#39;Volatility Is Certainly Being Fed By Trump 2.0 Moves,&#39; Says Expert

Energy stocks

Eurozone

Trading Ideas

DBGI

PRTG

QUBT

TNXP

VCNX

Crude Oil Down Over 1%; US Industrial Production Declines In November

Tenaya Therapeutics Inc

Health Care

Press Releases

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

General

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Financing

Tenaya Therapeutics Announces Proposed Public Offering

Tenaya Therapeutics Announces Pricing of Public Offering

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Anixa Biosciences

C4 Therapeutics

Coherus BioSciences

Coya Therapeutics

Editas Medicine

Elicio Therapeutics

Elutia

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Fate Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genelux

Immunic

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Renovaro

Regulus Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Instil Bio

Vor Biopharma

Vaxart

XBiotech

HC Wainwright & Co.

Canaccord Genuity

Morgan Stanley

Chardan Capital

Comments

Tenaya Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga